Lineage Aims to Solve Global Corneal Blindness with Off-the-Shelf Cells

CARLSBAD, CA – July 13, 2026 – For the more than 12 million people worldwide waiting for a corneal transplant, the future of their vision often depends on the generosity of a donor. It’s a precarious wait, with a staggering global deficit of only one available donor cornea for every 70 diseased eyes. This critical shortage leaves millions at risk of irreversible vision loss. Now, Lineage Cell Therapeutics (NYSE American and TASE: LCTX) is working to change that equation entirely. The clinical-stage biotechnology company has just announced a significant step forward for its COR1 program, a novel cell therapy designed to provide an unlimited, “off-the-shelf” supply of corneal cells to treat diseases that are a leading cause of blindness.

Lineage has confirmed that its COR1 program is advancing into in-vivo animal testing, a pivotal milestone that moves the therapy from the lab bench closer to human clinical trials, with initial data expected to be generated this year.

A Crisis of Vision and a Shortage of Solutions

Corneal endothelial disease is a devastating group of conditions that quietly robs people of their sight. The corneal endothelium is a single layer of specialized cells, known as corneal endothelial cells (CEnCs), on the inner surface of the cornea. These cells act as the cornea’s pump, maintaining the perfect fluid balance required for transparency. In diseases like Fuchs’ endothelial corneal dystrophy (FECD), which affects millions of adults, these cells progressively die off. Without the pump function, the cornea swells with fluid, becomes cloudy, and vision is lost.

For decades, the only effective treatment has been corneal transplantation, a delicate surgery where a surgeon replaces the diseased endothelial layer with healthy tissue from a deceased donor. While transformative, this procedure is entirely dependent on a limited supply of donor tissue. The global shortage is compounded by logistical challenges, including the donor tissue's brief shelf-life, variability in quality, and the need for highly specialized surgical centers. The result is a massive unmet medical need, where a treatable condition leads to preventable blindness simply due to a lack of supply.

Engineering a Solution: The COR1 Program

Lineage is tackling this crisis head-on with its COR1 program. Instead of relying on donor tissue, the company is using its proprietary cell therapy platform to manufacture pure, functional CEnCs in a lab. These cells are designed to be injected into the eye in a minimally invasive procedure, where they can repopulate the cornea's inner surface and restore its pumping function. The company has now successfully manufactured these cells at a scale and quality that meet its internal criteria for advancement into preclinical animal studies.

“Millions of people are candidates for corneal transplants yet there is only one donor for every 70 diseased eyes globally. The quality and supply of CEnC’s from cadaveric sources is limited by donor variability,” stated Brian M. Culley, Lineage CEO. “We believe we are well positioned to develop a consistent and ‘off-the-shelf’ allogeneic source of CEnCs from our proprietary AlloSCOPE platform, based in part on our expertise developed from OpRegen® and our other pipeline programs.”

Culley highlighted the promise of this approach, noting, “Cadaveric CEnCs have been approved in Japan to treat corneal endothelial disease, providing evidence for the efficacy of a cornea cell transplant. This work creates an inviting opportunity for us to develop a more consistent and cost-effective product option that may be able to better address the global shortage of donor cells.”

The Power of the Platform: Scalability and Consistency

The true innovation behind the COR1 program lies in the technology used to create it: the AlloSCOPE™ (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering) platform. This in-house technology platform is the engine for Lineage’s entire pipeline, designed from the ground up to solve the biggest challenges in regenerative medicine: manufacturing and logistics.

Unlike therapies that use a patient’s own cells or rely on one-off donors, AlloSCOPE starts with a single, well-characterized pluripotent cell line. From this single source, Lineage can direct the cells to become specialized cell types—in this case, CEnCs. This master cell bank can be expanded to create a working cell bank, which in turn can generate what the company projects to be millions of doses of the final cell therapy product. This creates a truly “off-the-shelf” solution: a consistent, quality-controlled product that can be manufactured on an industrial scale, frozen, and shipped to clinics anywhere in the world, ready for a simple “thaw-and-inject” procedure.

This approach directly addresses the shortcomings of cadaveric tissue. It eliminates concerns about donor variability and limited supply, while the frozen formulation provides a long shelf-life, dramatically simplifying logistics for hospitals and surgeons. Furthermore, Lineage is applying its AlloSCOPE “5D” manufacturing process, an advanced, large-scale production method designed to further reduce costs and make the therapy accessible to a global population.

Navigating a Competitive and Regulatory Landscape

Lineage is not alone in recognizing the immense need for a transplant alternative. The field of corneal cell therapy is an active area of innovation, with pioneering academic groups and other clinical-stage companies, particularly in Japan, also developing cell injection therapies. However, Lineage believes its powerful manufacturing platform provides a key competitive advantage.

By focusing on industrial-scale production and a convenient thaw-and-inject formulation from the outset, the company aims to deliver not just a clinical solution, but a commercially viable and globally distributable one. The ability to produce millions of consistent doses from a single cell line could be a crucial differentiator in a market desperate for a scalable product.

From a regulatory standpoint, the path for regenerative medicines is becoming clearer. The U.S. Food and Drug Administration (FDA) has established pathways like the Regenerative Medicine Advanced Therapy (RMAT) designation to help speed the development of promising therapies for serious conditions. A strong manufacturing and control (CMC) package is paramount for approval, and Lineage’s AlloSCOPE platform is specifically designed to generate the robust data on product consistency, purity, and potency that regulators require.

A Strategic Step for Lineage

The advancement of COR1 is more than just a scientific milestone; it's a significant strategic move for Lineage Cell Therapeutics. The program is an internally-developed and wholly-owned initiative, demonstrating the company’s ability to leverage its platform and expertise to build its own pipeline beyond high-profile partnerships, such as its collaboration with Roche and Genentech for a retinal therapy.

This successful expansion into a new ophthalmology indication validates the versatility of the AlloSCOPE platform and strengthens the company’s long-term value proposition. By developing a potential solution for one of the largest underserved patient populations in ophthalmology, Lineage is not only aiming to restore sight for millions but is also building a robust and diversified portfolio of next-generation cell therapies.